ACCESS Newswire·Aug 18, 2026, 4:05 PM ET

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics granted inducement awards to two newly hired employees on August 17, 2026, under its Amended & Restated Inducement Plan.
The aggregate awards included options to purchase 5,675 shares & restricted stock units for 1,500 shares of common stock.
The option exercise price was set at $155.10, matching the Nasdaq Global Market closing price on the grant date.
Option shares vest over four years with 25% vesting on the first anniversary & the remainder in equal monthly installments.
RSU shares vest annually over a four-year period with one-fourth vesting each year.
The compensation committee approved the awards as a material inducement in compliance with Nasdaq Marketplace Rule 5635(c)(4).
ICOTYDE launched in the U.S. in March 2026 for moderate-to-severe plaque psoriasis & is in Phase 3 trials for psoriatic arthritis, ulcerative colitis, & Crohn's disease.
An NDA for rusfertide to treat polycythemia vera is under priority review by the FDA.
The company maintains additional clinical & preclinical programs targeting oral IL-17 antagonists, obesity agonists, hepcidin mimetics, & IL-4 & amylin pathways.